David Amsellem
Stock Analyst at Piper Sandler
(4.02)
# 593
Out of 4,711 analysts
137
Total ratings
50.88%
Success rate
11.2%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $163 | $122.97 | +32.55% | 12 | Dec 12, 2024 | |
| VTRS Viatris | Reiterates: Neutral | $13 → $14 | $12.52 | +11.82% | 6 | Dec 6, 2024 | |
| OPTN OptiNose | Maintains: Overweight | $3 → $1 | $0.42 | +138.04% | 2 | Nov 13, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $9 → $11 | $7.78 | +41.39% | 4 | Nov 11, 2024 | |
| XERS Xeris Biopharma Holdings | Downgrades: Neutral | $3 | $3.49 | -14.04% | 4 | Nov 11, 2024 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $37 | $29.71 | +24.54% | 7 | Oct 25, 2024 | |
| INDV Indivior | Reiterates: Overweight | $15 → $16 | $11.66 | +37.22% | 4 | Oct 25, 2024 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $37 | $29.70 | +24.58% | 6 | Oct 11, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Overweight | $68 | $53.35 | +27.46% | 1 | Oct 11, 2024 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $38 → $67 | $51.40 | +30.35% | 5 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $35.43 | +1.61% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $131 → $159 | $135.42 | +17.41% | 8 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $6 | $3.09 | +94.17% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $66 | $39.14 | +68.63% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.47 | -59.84% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $18.98 | +121.29% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 → $20 | $22.09 | -9.46% | 9 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $14.58 | +64.61% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.65 | +173.97% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $23 | $10.31 | +123.08% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.45 | +371.91% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $90.73 | +24.55% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $1 | $0.42 | +136.63% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.28 | +22.52% | 3 | Oct 16, 2023 |
Jazz Pharmaceuticals
Dec 12, 2024
Reiterates: Overweight
Price Target: $163
Current: $122.97
Upside: +32.55%
Viatris
Dec 6, 2024
Reiterates: Neutral
Price Target: $13 → $14
Current: $12.52
Upside: +11.82%
OptiNose
Nov 13, 2024
Maintains: Overweight
Price Target: $3 → $1
Current: $0.42
Upside: +138.04%
Amneal Pharmaceuticals
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.78
Upside: +41.39%
Xeris Biopharma Holdings
Nov 11, 2024
Downgrades: Neutral
Price Target: $3
Current: $3.49
Upside: -14.04%
Alkermes
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $29.71
Upside: +24.54%
Indivior
Oct 25, 2024
Reiterates: Overweight
Price Target: $15 → $16
Current: $11.66
Upside: +37.22%
Collegium Pharmaceutical
Oct 11, 2024
Reiterates: Neutral
Price Target: $37
Current: $29.70
Upside: +24.58%
ANI Pharmaceuticals
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $53.35
Upside: +27.46%
Corcept Therapeutics
Sep 18, 2024
Maintains: Overweight
Price Target: $38 → $67
Current: $51.40
Upside: +30.35%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $35.43
Upside: +1.61%
Aug 29, 2024
Upgrades: Overweight
Price Target: $131 → $159
Current: $135.42
Upside: +17.41%
Aug 9, 2024
Maintains: Overweight
Price Target: $11 → $6
Current: $3.09
Upside: +94.17%
Aug 8, 2024
Maintains: Overweight
Price Target: $71 → $66
Current: $39.14
Upside: +68.63%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.47
Upside: -59.84%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $18.98
Upside: +121.29%
May 13, 2024
Reiterates: Overweight
Price Target: $19 → $20
Current: $22.09
Upside: -9.46%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $14.58
Upside: +64.61%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.65
Upside: +173.97%
Mar 5, 2024
Maintains: Overweight
Price Target: $18 → $23
Current: $10.31
Upside: +123.08%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.45
Upside: +371.91%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $90.73
Upside: +24.55%
Nov 14, 2023
Downgrades: Neutral
Price Target: $12 → $1
Current: $0.42
Upside: +136.63%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.28
Upside: +22.52%